Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. and is encouraging investors who suffered losses to discuss their legal options [1] Group 1 - The investigation pertains to securities purchased or acquired in REGENXBIO between February 9, 2022, and January 27, 2026 [1] - There is a deadline of April 14, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [1]

PayPal Holdings, Inc. (NASDAQ:PYPL) - The class action lawsuit alleges that PayPal misled investors regarding its revenue outlook and growth potential during the class period from February 25, 2025, to February 2, 2026 [6] - PayPal's fourth quarter and full fiscal year 2025 results, announced on February 3, 2026, revealed disappointing earnings and a withdrawal of its 2027 financial targets, leading to a stock price drop of over 20% [6] - The lawsuit claims that the company's optimistic growth plans were unrealistic and that the management failed to provide clear direction, contributing to operational issues [6] REGENXBIO Inc. (NASDAQ:RGNX) - The class action lawsuit involves allegations that REGENXBIO provided misleading information about its gene therapy product candidate RGX-111 during the class period from February 9, 2022, to January 27, 2026 [6] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a trial participant, resulting in a 17.8% decline in stock price from $13.41 to $11.01 in one day [6] - The lawsuit claims that the company made overly positive assertions about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety [6]

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2026 [3]. - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK,, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ...

Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 202 ...

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and the efficacy of its product candidate RGX-111 [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. - Defendants reportedly made positive assertions about RGX-111's trial success while concealing adverse facts about its efficacy and safety [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Regenxbio and certain of it ...